<DOC>
	<DOCNO>NCT02024789</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , 3-arm , parallel-group , placebo-controlled study evaluate efficacy safety RG1662 adults adolescent Down syndrome . Subjects randomize receive RG1662 either low high dose placebo orally twice daily 26 week .</brief_summary>
	<brief_title>A Study RG1662 Adults Adolescents With Down Syndrome ( CLEMATIS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>Individuals age 1230 year age inclusive Clinical diagnosis Down syndrome ( trisomy 21 ) confirm chromosomal analysis ( karyotyping ) Males , nonpregnant , nonlactating female . For female childbearing potential , strict contraceptive prevention require . Bodymass Index ( BMI ) 1842 1530 kg/m2 inclusive adult adolescent respectively Ability complete Clinical Evaluation Language Fundamentals ( CELF ) preschool 2 word class task Subjects must parent , reliable caregiver agree accompany subject clinic visit , provide information subject require protocol , ensure compliance medication schedule Study participant must sufficient language , vision hearing participate study evaluation , judge clinically investigator Subjects current DSM 5 diagnosis primary psychiatric diagnosis ( include ASD MDD ) Subjects history infantile spasm , West syndrome , LennoxGastaut syndrome , Early Infantile Epileptic Encephalopathy treatmentrefractory epilepsy associate cognitive developmental regression , severe head trauma CNS infection ( e.g . meningitis ) Subjects know suspected clinical seizure event type within 24 month prior screen Clinically relevant ECG abnormality screen baseline ; QTcF 450 m ; personal family history ( first degree relative ) congenital long QT syndrome Inadequate renal hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>